ClinicalTrials.gg
CompletedNCT03296800Updated Jul 1, 2021Results posted

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

A Phase 1 interventional study of Bexagliflozin and Probenecid in Type 2 Diabetes Mellitus, sponsored by Theracos. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-01.

Sponsored by Theracos · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies in Diabetes Mellitus, Type 2 by Theracos — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Theracos.

Enrollment
11th of 17
48 · median 78
Started
2017
with 4 others
Phase 1
9 of 17
none open now
Registered
15th of 17
by date

Among the 17 studies in Diabetes Mellitus, Type 2 by Theracos, this one is the 11th largest by enrollment, is one of 5 that started in 2017, is one of 9 in phase 1, and was the 15th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 17 studies in Diabetes Mellitus, Type 2 by Theracos is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Diabetes Mellitus, Type 2 by Theracos as a file.
02

Study summary

The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with three commonly prescribed medications, probenecid, verapamil or rifampin. The study is to evaluate how safe the study drug is and how well the study drug is tolerated when taken with probenecid, verapamil or rifampin.

Read the detailed description

In this study, a total of 48 healthy subjects were enrolled and assigned to one of three groups of 16 subjects. Each group participated in an open-label, non-randomized, fixed-sequence studies to assess potential interaction of bexagliflozin tablets, 20 mg with probenecid, rifampin or verapamil.

Sequence 1: Bexagliflozin/probenecid Sixteen healthy subjects were dosed with bexagliflozin, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.

Sequence 2: Bexagliflozin/rifampin Sixteen healthy subjects were dosed with bexagliflozin, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.

Sequence 3: Bexagliflozin/verapamil Sixteen healthy subjects were dosed with bexagliflozin, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Subjects meeting the following Criteria were included::

  1. Between 18 and 55 years of age at screening, inclusive, and in good health based on medical history, physical examination, and routine laboratory tests.
  2. Had a body-mass index () between 18.0 kg/m2 and 32.0 kg/m2 at screening, inclusive.
  3. Abstained from tobacco consumption for at least 3 months prior to screening.
  4. Had adequate venous access at multiple sites in both arms.
  5. Willing and able to be confined to the clinical research facility as required by the protocol.
  6. Able to comprehend the explanation of the and willing to provide written informed consent in accordance with institutional and regulatory guidelines.

Subjects who met any of the following criteria were excluded from the study:

  1. A history of allergy to drugs or latex (at the Investigator's discretion.)
  2. A history of alcohol or drug dependence in the last 12 months.
  3. A history of donation of 400 mL of whole blood within two months, 200 mL of whole blood within one month, or blood components within 14 days prior to the first dose.
  4. A history of prescription or over-the-counter (OTC) drug use within 14 days prior to the first dose.
  5. A history of vitamin preparation or supplement use (including St. John's Wort and ginseng) within 14 days prior to the first dose.
  6. A history of strenuous physical activity within 72 hours prior to dosing.
  7. A history of exposure to an drug within 30 days or 7 half-lives of the investigational drug, whichever was longer, prior to the first dose of investigational drug in this trial.
  8. A history of prior exposure to EGT0001474 or bexagliflozin at any time, or of exposure to any other SGLT2 inhibitors within 3 months from screening or of participation in previous bexagliflozin clinical trials.
  9. A history of consumption of probenecid, rifampin, or verapamil within 3 months of screening.
  10. A screening ECG that demonstrated any one of the following: heart rate >100 bpm, QRS >120 msec, >470 msec (corrected by Bazett's formula), PR >220 msec (a subject with PR >220 msec was generally to be excluded, but exceptions may have been allowed at the discretion of the Investigator), or any clinically significant arrhythmia.
  11. A sitting blood pressure that was above 140/90 mmHg at screening. If the sitting blood pressure at screening was above 140/90 mmHg, one repeat measurement could have been taken. Subjects were to be excluded if the repeated sitting blood pressure was above 140/90 mmHg, but exceptions may have been allowed at the discretion of the Investigator.
  12. A positive result for surface antigen (HBsAg), virus (HCV) antibody, or for urinary drug or cotinine tests.
  13. A history of (HIV) infection.
  14. A history of febrile illness within 5 days prior to the first dose of investigational drug.
  15. A history of vaccination (with the exception of the flu vaccine) within 30 days prior to the first dose of investigational drug.
  16. An estimated (eGFR) \< 80 mL/min/1.73 m2 or a history of kidney transplant.
  17. If male, who was not surgically sterile, unwilling to refrain from donating sperm, and/or unwilling to use appropriate when engaging in sexual intercourse for a period of 30 days after discharge from the clinic.
  18. Female subjects who were surgically sterile (i.e., have undergone partial or full hysterectomy, or bilateral oophorectomy) or were eligible if they tested negative on a urine pregnancy test.
  19. Evidence of anemia if selected for probenecid study.
  20. Evidence of abnormal liver function tests (total >1.5 x [ULN]); or (ALT) or aspartate aminotransferase (AST) >2.5 x ULN.
  21. If selected for the rifampin study, unwilling to refrain from the use of soft contact lenses during the study.
  22. Unwilling to forgo consumption of alcohol 72 hours pre admission and throughout the study.
  23. Unwilling to forgo consumption of grapefruit and grapefruit products from 7 days prior to dosing through discharge from the clinic.
  24. A history of recurrent yeast or urinary tract infections or any such infections in the 6 months prior to first dose.
  25. A history of gout, glucose-6-phosphate dehydrogenase deficiency, or nephrolithiasis if a candidate for the probenecid study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Bexagliflozin/probenecid

    Sixteen healthy subjects were dosed with bexagliflozin, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.

    Drug: Bexagliflozin · Drug: Probenecid

  • Experimental
    Bexagliflozin/rifampin

    Sixteen healthy subjects were dosed with bexagliflozin, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.

    Drug: Bexagliflozin · Drug: Rifampin

  • Experimental
    Bexagliflozin/verapamil

    Sixteen healthy subjects were dosed with bexagliflozin, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.

    Drug: Bexagliflozin · Drug: Verapamil

Interventions

  • Bexagliflozin 20 mg, tablet; qd

    Also known as: EGT0001442, EGT0001474

  • Probenecid tablets, 500 mg; bid

    Also known as: Probalan

  • Rifampin, 600 mg (2 x 300 mg capsules); qd

    Also known as: Rifadin

  • Verapamil hydrochloride tablet, 120 mg; qd

    Also known as: Verelan

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Observed Plasma Concentration)

    Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).

    Time frame: Up to 48 hours

  2. Tmax (Time of Maximum Observed Plasma Concentration)

    Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).

    Time frame: Up to 48 hours

  3. T1/2 (Apparent Terminal Elimination Half-life)

    Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).

    Time frame: Up to 48 hours

  4. AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

    Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).

    Time frame: Up to 48 hours

Secondary outcomes

  1. Urinary Glucose Excretion 0-48 hr

    Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics.

    Time frame: 0 to 48 hours

07

Results

Posted Apr 27, 2021

Participant flow

Participant flow — Overall Study
MilestoneBexagliflozin, Then Probenecid, Then Bexagliflozin and ProbenecidBexagliflozin, Then Rifampin, Then Bexagliflozin and RefampinBexagliflozin, Then Verapamil and Bexagliflozin
Started161616
Completed161616
Not completed000

Outcome measures

PrimaryCmax (Maximum Observed Plasma Concentration)

Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).

Time frame:
Up to 48 hours
Reported as:
Geometric mean · ng/mL
Cmax (Maximum Observed Plasma Concentration)
ng/mLStudy 1: Bexagliflozin AloneStudy 1: Bexagliflozin and ProbenecidStudy 2: Bexagliflozin AloneStudy 2: Bexagliflozin and RifampinStudy 3: Bexagliflozin AloneStudy 3: Bexagliflozin and Verapamil
Cmax (Maximum Observed Plasma Concentration)161.675 ± 28.673193.366 ± 22.09897.811 ± 53.903117.001 ± 60.097159.355 ± 35.396169.000 ± 24.727
Statistical analysis
  • Study 1: Bexagliflozin Alone vs Study 1: Bexagliflozin and Probenecid · Point estimate (%): 118.66 · 90% CI 111.12 to 126.72Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with treatment as a fixed effect, and subject as a random effect.
  • Study 2: Bexagliflozin Alone vs Study 2: Bexagliflozin and Rifampin · Point estimate (%): 119.62 · 90% CI 94.39 to 151.59
  • Study 3: Bexagliflozin Alone vs Study 3: Bexagliflozin and Verapamil · Point estimate (%): 106.05 · 90% CI 88.81 to 126.65
PrimaryTmax (Time of Maximum Observed Plasma Concentration)

Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).

Time frame:
Up to 48 hours
Reported as:
Median · hours
Tmax (Time of Maximum Observed Plasma Concentration)
hoursBexagliflozin/ProbenecidBexagliflozin/RifampinBexagliflozin/Verapamil
Bexagliflozin alone2.000 (2.000 to 4.000)2.000 (2.000 to 4.083)3.0 (2.000 to 8.000)
Bexagliflozin + additional drug3.000 (2.000 to 4.017)2.000 (1.017 to 4.000)3.000 (2.000 to 4.000)
PrimaryT1/2 (Apparent Terminal Elimination Half-life)

Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).

Time frame:
Up to 48 hours
Reported as:
Geometric mean · hours
T1/2 (Apparent Terminal Elimination Half-life)
hoursBexagliflozin/ProbenecidBexagliflozin/RifampinBexagliflozin/Verapamil
Bexagliflozin alone12.090 ± 35.95012.190 ± 36.96610.709 ± 44.103
Bexagliflozin + additional drug13.894 ± 24.8065.318 ± 49.74011.675 ± 48.222
PrimaryAUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)

Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).

Time frame:
Up to 48 hours
Reported as:
Geometric mean · hr*ng/mL
AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
hr*ng/mLStudy 1: Bexagliflozin AloneStudy 1: Bexagliflozin/ProbenecidStudy 2: Bexagliflozin AloneStudy 2: Bexagliflozin/RifampinStudy 3: Bexagliflozin AloneStudy 3: Bexagliflozin/Verapamil
AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)1118.741 ± 23.2901583.188 ± 23.676698.254 ± 43.945601.334 ± 49.8701025.101 ± 25.7461003.931 ± 21.571
Statistical analysis
  • Study 1: Bexagliflozin Alone vs Study 1: Bexagliflozin/Probenecid · Point estimate (%): 140.98 · 90% CI 131.39 to 151.26Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with treatment as a fixed effect, and subject as a random effect.
  • Study 2: Bexagliflozin Alone vs Study 2: Bexagliflozin/Rifampin · Point estimate (%): 86.12 · 90% CI 70.24 to 105.59Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with treatment as a fixed effect, and subject as a random effect.
  • Study 3: Bexagliflozin Alone vs Study 3: Bexagliflozin/Verapamil · Point estimate (%): 97.93 · 90% CI 90.26 to 106.26Point Estimate is the estimated ratio of exponentiated mean difference of log-transformed PK parameter from ANOVA. Confidence interval is obtained from ANOVA with treatment as a fixed effect, and subject as a random effect.
SecondaryUrinary Glucose Excretion 0-48 hr

Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics.

Time frame:
0 to 48 hours
Reported as:
Mean · g
Urinary Glucose Excretion 0-48 hr
gStudy 1: Bexagliflozin AloneBexagliflozin/ProbenecidStudy 2: Bexagliflozin AloneBexagliflozin/RifampinStudy 3: Bexagliflozin AloneBexagliflozin/Verapamil
Pre-dose (-12 - 0 hours)0.02 ± 0.0240.47 ± 1.1600.02 ± 0.0140.12 ± 0.1800.02 ± 0.0181.37 ± 1.476
0 - 12 hours post-dose25.04 ± 5.57925.90 ± 5.21431.50 ± 9.27231.40 ± 7.36331.14 ± 5.81431.46 ± 14.835
12 - 24 hours post-dose21.28 ± 7.34720.92 ± 4.35819.43 ± 6.86315.72 ± 7.25922.30 ± 3.93320.51 ± 5.940
24 - 36 hours post-dose22.04 ± 7.13622.10 ± 6.82621.51 ± 7.66816.32 ± 6.37024.54 ± 6.51720.94 ± 6.745
36 - 48 hours post-dose11.15 ± 5.4479.53 ± 3.1146.99 ± 3.4403.41 ± 2.31811.31 ± 4.9974.78 ± 2.941
0 - 24 hours post-dose47.73 ± 9.12546.82 ± 8.53050.93 ± 15.60647.12 ± 13.79053.44 ± 8.71251.97 ± 13.658
0 - 48 hours post-dose81.67 ± 16.08378.44 ± 15.65379.43 ± 24.49066.86 ± 19.56489.29 ± 16.46177.69 ± 16.497

Adverse events

Collected over The adverse event data were collected from Day 0 up to Day 7 for study 1, Day 0 up to Day 8 for study 2 and Day 0 up to Day 6 for study 3 after drug administration. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Study 1: Bexagliflozin Alone0/16 (0%)0/16 (0%)0/16 (0%)
Study 1: Bexagliflozin and Probenecid0/16 (0%)0/16 (0%)1/16 (6.3%)
Study 2: Bexagliflozin Alone0/16 (0%)0/16 (0%)0/16 (0%)
Study 2: Bexagliflozin and Rrifampin0/16 (0%)0/16 (0%)0/16 (0%)
Study 3: Bexagliflozin Alone0/16 (0%)0/16 (0%)2/16 (12.5%)
Study 3: Bexagliflozin and Verapamil0/16 (0%)0/16 (0%)0/16 (0%)
Most frequent other events
Most frequent other events
EventStudy 1: Bexagliflozin AloneStudy 1: Bexagliflozin and ProbenecidStudy 2: Bexagliflozin AloneStudy 2: Bexagliflozin and RrifampinStudy 3: Bexagliflozin AloneStudy 3: Bexagliflozin and Verapamil
DiarrheaGastrointestinal disorders0/161/160/160/160/160/16
Gastrointestinal sounds abnormalGastrointestinal disorders0/161/160/160/160/160/16
LacerationInjury, poisoning and procedural complications0/160/160/160/161/160/16
PresyncopeNervous system disorders0/160/160/160/161/160/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bexagliflozin, Then Probenecid, Then Bexagliflozin and ProbenecidBexagliflozin, Then Rifampin, Then Bexagliflozin and RefampinBexagliflozin, Then Verapamil and BexagliflozinTotal
Mean38.4 ± 9.6935.3 ± 10.7237.8 ± 11.2437.2 ± 10.43
Sex: Female, Male
Sex: Female, Male(Participants)Bexagliflozin, Then Probenecid, Then Bexagliflozin and ProbenecidBexagliflozin, Then Rifampin, Then Bexagliflozin and RefampinBexagliflozin, Then Verapamil and BexagliflozinTotal
Female35412
Male13111236
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bexagliflozin, Then Probenecid, Then Bexagliflozin and ProbenecidBexagliflozin, Then Rifampin, Then Bexagliflozin and RefampinBexagliflozin, Then Verapamil and BexagliflozinTotal
Hispanic or Latino108826
Not Hispanic or Latino68822
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bexagliflozin, Then Probenecid, Then Bexagliflozin and ProbenecidBexagliflozin, Then Rifampin, Then Bexagliflozin and RefampinBexagliflozin, Then Verapamil and BexagliflozinTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American52512
White11141136
More than one race0000
Unknown or Not Reported0000
Weight
Weight(kg)Bexagliflozin, Then Probenecid, Then Bexagliflozin and ProbenecidBexagliflozin, Then Rifampin, Then Bexagliflozin and RefampinBexagliflozin, Then Verapamil and BexagliflozinTotal
Mean81.3 ± 10.5974.1 ± 11.3178.9 ± 9.2178.7 ± 10.57
Height
Height(cm)Bexagliflozin, Then Probenecid, Then Bexagliflozin and ProbenecidBexagliflozin, Then Rifampin, Then Bexagliflozin and RefampinBexagliflozin, Then Verapamil and BexagliflozinTotal
Mean170.9 ± 8.28169.2 ± 8.38172.1 ± 10.17170.7 ± 8.88
BMI
BMI(kg/m^2)Bexagliflozin, Then Probenecid, Then Bexagliflozin and ProbenecidBexagliflozin, Then Rifampin, Then Bexagliflozin and RefampinBexagliflozin, Then Verapamil and BexagliflozinTotal
Mean27.8 ± 2.7325.9 ± 3.3126.7 ± 2.4627.0 ± 3.50
08

Study locations

1 site
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Dec 2017, 2 months.

Results were first posted in Apr 2021, 3 years 4 months after primary completion.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2017
First posted
Sep 28, 2017
StartActual
Sep 27, 2017
Primary completionActual
Dec 6, 2017
CompletionActual
Dec 6, 2017
Results first posted
Apr 27, 2021
Last update
Jul 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03296800
Lead sponsor
Theracos
Responsible party
Sponsor
First posted
Sep 28, 2017
Start date
Sep 27, 2017
Primary completion
Dec 6, 2017
Completion
Dec 6, 2017
Results posted
Apr 27, 2021
Last update
Jul 1, 2021

Study contacts

Mason Freeman, M.D.
study director · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion